Sophia Genetics SA 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
SOPHiA GENETICS SA reported a 19% increase in revenue to $77.3 million for 2025, driven by platform adoption and analysis volume, while navigating an ongoing patent infringement lawsuit and increasing net losses.
NASDAQ
20-F: Sophia Genetics SA Releases 20-F Filing, Highlights Financial Performance and Strategic Outlook
Sophia Genetics SA's 20-F filing provides a comprehensive overview of the company's financial results, strategic initiatives, and risk factors for the fiscal year ended December 31, 2024.
NASDAQ
Sophia Genetics' 20-F filing reveals its financial performance, strategic direction, and potential risks for the fiscal year ended December 31, 2023.